Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances.
Bone metastases can accompany any metastatic tumor type; however, certain tumors have a predisposition to forming bone metastases. These include breast cancer, prostate cancer, thyroid carcinoma, multiple myeloma, and renal cell carcinoma. Typically, metastases are osteolytic, that is, they resorb bone resulting in decreased bone mineral content. An exception to this rule is prostate cancer bone metastases as they have a combination of osteolytic activity and osteoblastic activity (i.e., induce bone mineral production). A small portion of patients with breast cancer bone metastases have primarily osteoblastic activity. Both osteolytic activity and osteoblastic activity result in weakening of the normal healthy bone and predispose the patient to a variety of skeletalrelated events.
The skeletal-related events associated with bone metastasis result in significant complications that diminish the quality of life in affected patients. These complications include bone pain, impaired mobility, pathological fracture, spinal cord compression, and symptomatic hypercalcemia [Galasko, 1986; Coleman, 1997; Moul and Lipo, 1999] . Despite advances in the diagnosis and management of primary localized cancers, advanced disease with skeletal metastasis remains incurable. Current therapeutic modalities are mostly palliative, and may include hormonal therapy, pharmacological management of bone pain, radiotherapy for pain and spinal cord compression [Szostak and Kyprianou, 2000] , various chemotherapy regimens, and the use of bisphosphonates to inhibit osteoclast activity [Papapoulos et al., 2000] . Although these therapies may have palliative effects, they typically do not cure the cancer. Understanding the mechanisms that promote bone metastasis may help identify new therapeutic targets to stop the progression of this devastating aspect of cancer. We highlight several active areas of bone metastasis research below.
CHEMOTAXIS
Chemotaxis is a basic physiological process through which cells migrate along a chemical gradient. For example, hematopoietic stem cells (HSC) express the receptor for stromal-derived factor (SDF), CXCR4. Bone marrow is a source of SDF and HSC migrate down the chemotactic gradient to the bone marrow. Similar to the HSCs, it was observed that melanoma, breast cancer and prostate cancer cells express CXCR4 [Fourcin et al., 1996; Muller et al., 2001; Taichman et al., 2002] , which allows them to target bone. Since these initial observations, it has been reported that many cancer types express CXCR4 and co-opt the HSC chemotactic system. SDF-1 promotes chemotaxis through upregulation of migration in the target cells [Libura et al., 2002] . In terms of prostate cancer, it has been reported that androgen receptor negatively affects regulation of CXCR4 [Akashi et al., 2006] , which suggest that loss of androgen receptor enhances prostate cancer migration. This may be important to the development of metastasis because as prostate cancer progresses, androgen receptor expression is altered. In breast cancer, NFkB was shown to upregulate chemotaxis through inducing CXCR4 expression in breast cancer cells [Helbig et al., 2003 ]. NFkB activity is often upregulated secondary to inflammatory processes. Thus, this observation suggests that inflammation may promote metastasis through NFkB-mediated induction of CXCR4. As more research in this area is performed, it is likely that some of these mechanisms through which CXCR4 is regulated and promotes metastasis will be found relevant to multiple tumor types.
Due to its importance in the metastatic process, many efforts have been focused on targeting the CXCR4:SDF-1 axis. Towards this end, cancer investigators have taken advantage of the fact that human immunodeficiency virus (HIV) uses CXCR4 as a co-receptor and there is an armentarium of anti-HIV drugs that target CXCR4 activity [Juarez et al., 2004; Tsutsumi et al., 2007] . For example, T140, a peptide analog of CXCR4, was shown to decrease pulmonary metastasis in a murine model of breast cancer [Tamamura et al., 2003] . In another strategy, bisphosphonates, compounds that target osteoclasts, have been shown to decrease CXCR4 in breast [Denoyelle et al., 2003 ] and prostate cancer [Miwa et al., 2005] . As these compounds are developed and tested in clinics they may make an impact on cancer metastasis to bone.
THE BONE MICROENVIRONMENT
The final target site where metastatic cells grow and develop into clinically relevant metastases, termed the metastatic microenvironment, is clearly a key regulator of metastasis. This concept, first described as ''the seed and soil'' hypothesis by Paget [1829] , posits that the metastatic microenvironment (i.e., the ''soil'') must contain the appropriate elements for cancer cells (i.e., the ''seed'') to establish clinically detectable metastases. This concept is supported by the findings that although tumor cells are often circulating throughout the body their presence does not predict the development of metastases [Morgan et al., 2007; Pfitzenmaier et al., 2007] . Additionally, the observation that specific tumor types favor specific metastatic sites further supports the specificity of metastatic niches. For example, colon cancer selectively metastasizes to liver [Zvibel et al., 2000] and prostate cancer preferentially metastasizes to bone [Shah et al., 2004] . Identifying the cellular and molecular components of the microenvironment that promote development of bone metastasis has identified targets to block the development of metastases.
RECEPTOR ACTIVATOR OF NFkB LIGAND AND OSTEOPROTEGERIN
The metastasis of prostate cancer to bone is accompanied by a disruption in the normal bone remodeling equilibrium, although the mechanisms through which this occurs are largely unknown at present. In healthy adults, the regulated destruction (resorption or lysis) of normal lamellar bone matrix by large multinucleated osteoclasts is tightly coupled to the consequent formation of new bone by osteoblasts, such that lysis and formation are balanced (reviewed in Manolagas and Jilka [1995] ). However, in prostate cancer bone metastasis, bone lysis is stimulated at sites of tumor growth and excess woven bone is synthesized [Clarke et al., 1991] . This results in a general increase in both bone turnover and volume, although woven bone has less collagen and therefore less tensile strength than normal and is more susceptible to fracture. Evidence suggests that lysis is a prerequisite for the establishment of tumor cells in bone [Roland, 1958; Nielsen et al., 1991] , therefore understanding the regulation of bone resorption may suggest mechanisms through which tumors can develop in bone and may indicate novel therapeutic targets.
In normal bone, osteoblastic cells regulate osteoclastogenesis and osteoclast activity by interacting with mononuclear hematopoietic osteoclast precursors [Roodman, 1996] . The molecular mediators of this interaction were shown to be the osteoblast-expressed proteins, osteoprotegerin (OPG) and receptor activator of NFkB ligand (RANKL). Binding of RANKL to the osteoclast precursor-expressed RANK initiates a cascade of intracellular signals that culminates in the acquisition and activation of the osteoclast phenotype [Lacey et al., 1998; Yasuda et al., 1998a] . The absolute requirement of this interaction for osteoclastogenesis was shown by the generation of transgenic ranklÀ/À and rankÀ/À mice that developed severely hyperdense bones due to an absence of osteoclasts [Dougall et al., 1999; Kong et al., 1999] . Furthermore, administration of soluble extracellular RANKL to mice resulted in hypercalcemia and reduced bone volume, concomitant with a doubling of osteoclast size [Lacey et al., 1998 ]. The soluble glycoprotein OPG regulates excessive bone resorption by acting as a soluble decoy receptor for RANKL [Simonet et al., 1997] , and therefore neutralizes its interaction with RANK, abrogating osteoclast formation, activation and survival in vitro [Yasuda et al., 1998a,b] and in vivo [Lacey et al., 1998 ]. The crucial role of OPG in bone remodeling was demonstrated using transgenic opgÀ/À mice, which showed uncontrolled bone resorption and severe osteoporosis [Mizuno et al., 1998 ]. These studies suggest that the balance between RANKL and OPG determines the extent of bone resorption, in that a relative decrease in OPG results in excessive resorption and a relative increase in OPG inhibits resorption.
Expression of OPG, RANKL and/or RANK are dysregulated in a number of cancers in bone, including osteoclastoma [Atkins et al., 2000] , breast cancer [Lau et al., 2006; Kapoor et al., 2007] and prostate cancer [Brown et al., 2001; Perez-Martinez et al., 2007] , suggesting that these proteins may be involved in tumormediated bone destruction. In the case of breast cancers, it appears they express OPG and RANK but not RANKL [Thomas et al., 1999] or that RANKL expression is inversely related to estrogen receptor expression [Cross et al., 2006] . However, co-culture with hematopoietic bone marrow cells and osteoblasts resulted in a net increase in RANKL expression, suggesting an indirect mechanism through which localized bone lysis may occur in breast cancer bone metastasis, by activation of osteoclast precursors [Thomas et al., 1999] . This was supported using a murine in vitro model in which interactions between mouse breast cancer cells and bone marrow cells similarly resulted in a net increase in RANKL activity [Chikatsu et al., 2000] . Furthermore, it has been suggested that breast cancer can induced tumor-associated macrophages (TAMs) to differentiate into osteoclasts through RANKL-dependent and -independent mechanisms [Lau et al., 2006] . The cancer-stromal interaction is also critical in multiple myeloma, where co-culture produced a net increase in RANKL expression and in osteoclastogenesis that was inhibited by addition of soluble RANK [Pearse et al., 2001] . The production of active soluble RANKL by prostate cancer cells in vitro has been implicated as a mechanism through which prostate cancer cells can directly initiate osteoclastogenesis and therefore stimulate bone resorption [Zhang et al., 2001] .
Several exciting and provocative studies have examined the therapeutic uses of soluble RANK and OPG in the treatment of hematological and solid tumors in bone [Dougall and Chaisson, 2006b] . As a fusion protein with human IgG, RANK has proven efficacious in the inhibition of bone resorption in a mouse model of humoral hypercalcemia of malignancy as induced by PTHrP administration [Oyajobi et al., 2001] , and in the prevention of myeloma-induced osteoclastic bone destruction in a SCID-human model [Pearse et al., 2001 ] and prostate cancer model [Zhang et al., 2003] . In vitro experiments treating osteoclastoma-derived cells with OPG reduced the number of mature osteoclasts and inhibited bone resorption [Atkins et al., 2001] . Dramatic decreases in the numbers of mature osteoclasts and in the size and/or number of lesions in bone were observed following the treatment with OPG of mice carrying human breast cancer cells [Morony et al., 2001] , murine multiple myeloma [Croucher et al., 2001] , and human prostate cancer cells [Zhang et al., 2001] . In human prostate cancer cells, OPG has been shown to be a survival factor through its ability to inhibit TRAIL-mediated apoptosis [Holen et al., 2002] . These studies suggest that in bone metastatic tumors, inhibition of the primary resorptive stage may be sufficient to inhibit tumor establishment and halt progression of disease, even in those tumors that have primarily an osteoblastic phenotype. Importantly, treatment with OPG has also been demonstrated to block pain-related behavior in mice carrying bone cancers [Honore et al., 2000; Luger et al., 2001] . Development of OPG peptide mimetics may also offer some promise to sequester RANKL activity [Heath et al., 2007] . Although these previous studies provide proof of concept that blocking RANKL can impact skeletal metastasis, currently, the most likely clinical candidate to target RANKL is Denosumab (AMG 162), a fully human monoclonal antibody that can bind and inhibit human RANKL [Dougall and Chaisson, 2006a] . A phase 1 clinical trial in patients with multiple myeloma or breast carcinoma with bone metastases showed that a single subcutaneous injection of denosumab caused rapid and sustained suppression of bone turnover markers and was well tolerated. While studies are at an early stage at present, it appears that therapeutic targeting of the OPG/RANKL/RANK proteins holds great promise for treatment of bone metastases.
BISPHOPHONATES
Bisphosphonates are a group of chemicals that inhibit osteoclast activity resulting in decreased bone resorption and thus have received much attention as inhibitors of clinical complications of bone metastases [Mundy, 1999; Diel et al., 2000; Major et al., 2000] . Bisphosphonates work directly on osteoclasts to induce their apoptosis [Fleisch, 1997; Rowe et al., 1999] . Animal studies have demonstrated that bisphosphonates can diminish tumor-induced osteoclastogenesis and osteolysis [Hall and Stoica, 1994; Yoneda et al., 1997 Yoneda et al., , 2000 Kurth et al., 2000; Clohisy et al., 2001] . Although, in some instances, it appears to only reduce tumor-induced lysis, but not tumor burden [Dallas et al., 1999] . Studies in breast cancer and myeloma patients have shown that these agents markedly inhibit the progression of bone disease resulting in improved survival and decreased morbidity from bone pain and fracture [Apperley and Croucher, 1999; Lipton, 2000] . These results have led to their incorporation into standard treatment regimens for skeletal metastases associated with these cancers.
In addition to inhibiting osteoclast survival, bisphosphonates may have direct effects on tumor cells [Shipman et al., 1998b] . For example, several bisphosphonates induce apoptosis in myeloma cells [Aparicio et al., 1998; Shipman et al., 1998a; Takahashi et al., 2001] . However, this is not the case for all bisphosphonates [Shipman et al., 2000] . In addition to inducing apoptosis, bisphosphonates have been shown to inhibit breast carcinoma cell adhesion to bone [Magnetto et al., 1999] . Furthermore, alendronate blocked collagen degradation and MMP release from prostate cancer cells [Stearns, 1998; Stearns and Wang, 1998 ]. Taken together, these findings suggest that bisphosphonate action is not limited to inhibition of osteoclasts.
Studies of bisphosphonates use in patients with prostate cancer skeletal metastases have generally shown a decrease in bone pain although some studies have shown no benefit [Harvey and Lipton, 1996; Pelger et al., 1998; Heidenreich et al., 2001] . A recent randomized study of the oral bisphosphonate clodronate showed an encouraging decrease in the rate of progression to symptomatic bone metastases in men with prostate cancer [Fernandez-Conde et al., 1997] . Consistent with this observation is the finding that zoledronic acid is a third generation bisphosphonate that has demonstrated significantly increased activity in preclinical models when compared to early agents in this class. Exposure of prostate cancer cell lines to zoledronic acid results in marked inhibition of cell proliferation suggesting that this agent may have a direct antitumor effect beyond its ability to inhibit osteoclast activity [Coleman, 2000; Dearnaley and Sydes, 2001] . Zoledronic acid also has been shown to inhibit the invasion of prostate carcinoma cell lines in vitro [Boissier et al., 2000] . Clinical studies have demonstrated efficacy in treating hypercalcemia of malignancy, leading to recent FDA approval for use in this clinical setting [Major et al., 2001] . Treatment with zoledronic acid results in a significant and sustained decrease in markers of bone metabolism. However, osteonecrosis of the jaw (ONJ) has been recognized as a serious complication of bisphosphonate therapy [Mortensen et al., 2007] . It is not clear if this is due to generalized inhibition of osteoclast activity induced by bisphosphonates, in which case inhibition of RANKL may also cause ONJ, or if this is specific to bisphosphonates. It has been suggested that prior existing dental pathology may underlie some of the ONJ cases, but this is not clearly known .
SUMMARY
Bone metastases are a severe consequence of many cancers. Advances in the biology of bone metastases have led to new therapies that target their establishment and progression in animal models. These therapies have proven efficacious in certain clinical circumstances and many are undergoing evaluation in clinical trials. The majority of therapies are targeted at inhibiting the osteolytic activity induced by the cancer; however, others, such as inhibition of SDF-1 activity, are directed at inhibiting various components of the metastatic cascade such as migration. In some instances, therapies, such as chronic bisphosphonate administration, may actually have severe clinical consequences indicating the need to continually increase our understanding of the pathophysiology of bone metastasis and the need to continue developing improved therapeutics. Additional research in the area of mechanisms of bone metastasis may lead to additional promising therapies in the future.
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